Previous 10 | Next 10 |
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs) , today announced an agreement with SoftBank Corp. (“SoftBank”) to develop a Japanese-language digital ther...
A prescription digital therapeutic ("PDT") from Pear Therapeutics led to reductions in insomnia severity over a six-month period. Another study, in older adults with chronic insomnia, found the PDT, known as Somryst, led to insomnia reduction over 12 months. In the first study, call...
Interim data from DREAM, a fully virtual, decentralized study, found treatment with Somryst® achieved significant and meaningful reductions in insomnia severity through six months 1 Results from a study evaluating older adults with chronic insomnia, ...
Better Therapeutics (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company, is trading ~10% higher in the pre-market Tuesday after announcing data from its pivotal trial of BT-001 involving adults with type 2 diabetes. BT-001 is an experimental PDT platform used to digital...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host a conference call and webcast at 4:30 p.m. ET on Monday, March 28, 2022, to discuss its fi...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the 42 nd Annual Cowen Healthcare Conference being held virtually on Wed...
CMS establishes new Level II HCPCS code for Prescription Digital Behavioral Therapy, FDA Cleared, per Course of Treatment to describe prescription digital therapeutics (PDTs) including Pear’s PDTs for the treatment of substance use disorder (reSET®), opioid use disor...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in Citi’s 2022 Virtual Healthcare Conference on Thursday, February 24. C...
reSET ® and reSET-O ® are the only FDA-authorized prescription digital therapeutics (PDTs) for the treatment of substance use disorder (SUD) and opioid use disorder (OUD), respectively, and the first PDTs available in Spanish Research shows nine out of 10 H...
State of Michigan to provide funding towards the treatment of substance use and opioid use disorders with prescription digital therapeutics (PDTs), giving Michiganders access to Pear’s reSET® and reSET-O® Pear Therapeutics, Inc. (Nasdaq: PEAR), the leade...